236 related articles for article (PubMed ID: 36812126)
1. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
3. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
4. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.
Liu ZS; Jing CL
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481
[TBL] [Abstract][Full Text] [Related]
5. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
6. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
7. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.
Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG
Biochem Genet; 2023 Dec; ():. PubMed ID: 38108937
[TBL] [Abstract][Full Text] [Related]
8. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
[TBL] [Abstract][Full Text] [Related]
10. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
12.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
14. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
15. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
Liu J; Ji C; Wang Y; Zhang C; Zhu H
Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
[TBL] [Abstract][Full Text] [Related]
16. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
17. Construction of a prognostic model of luteolin for endometrial carcinoma.
Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
Front Oncol; 2022; 12():923641. PubMed ID: 35719911
[TBL] [Abstract][Full Text] [Related]
19. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
20. Endoplasmic reticulum stress related IncRNA signature predicts the prognosis and immune response evaluation of uterine corpus endometrial carcinoma.
Chen J; Shen L; Yang Y
Front Oncol; 2022; 12():1064223. PubMed ID: 36686816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]